AVIR
Atea Pharmaceuticals Inc.
$2.93
+$0.05(+1.74%)
45
Overall
--
Value
45
Tech
--
Quality
Market Cap
$235.69M
Volume
267.62K
52W Range
$2.46 - $4.02
Target Price
$6.00
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | $48.6M | $351.4M | -- | -- | -- | ||
| Total Revenue | $48.6M | $351.4M | -- | -- | -- | ||
| GROSS PROFIT | |||||||
| Gross Profit | $48.6M | $351.4M | -- | -- | -- | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $59.7M | $213.0M | $130.7M | $164.2M | $192.9M | ||
| Research & Development | $38.0M | $167.2M | $81.9M | $114.2M | $144.1M | ||
| Research Expense | $38.0M | $167.2M | $81.9M | $114.2M | $144.1M | ||
| Selling, General & Administrative | $21.6M | $45.8M | $48.7M | $49.9M | $48.8M | ||
| General & Administrative Expenses | $21.6M | $45.8M | $48.7M | $49.9M | $48.8M | ||
| Salaries & Wages | -- | -- | -- | $49.4M | $51.8M | ||
| Depreciation & Amortization | $19.0K | $29.0K | $260.0K | $416.0K | $416.0K | ||
| Depreciation & Amortization | $19.0K | $29.0K | $260.0K | $416.0K | $416.0K | ||
| Other Operating Expenses | $303.0K | $318.0K | -- | -- | -- | ||
| OPERATING INCOME | |||||||
| Operating income | $-11.0M | $138.4M | $-130.7M | $-164.2M | $-192.9M | ||
| EBITDA | $-11.0M | $138.4M | $-130.4M | $-134.5M | $-167.0M | ||
| NON-OPERATING ITEMS | |||||||
| Intinc | $83.0K | $213.0K | $11.2M | $29.2M | $25.5M | ||
| Net Non-Operating Interest Income/Expense | $83.0K | $213.0K | $11.2M | $29.2M | $25.5M | ||
| Other Income/Expense | $-540.0K | -- | -- | -- | -- | ||
| Other Special Charges | $540.0K | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-11.0M | $138.4M | $-130.7M | $-134.9M | $-167.5M | ||
| Pre-Tax Income | $-10.9M | $138.6M | $-119.5M | $-134.9M | $-167.5M | ||
| INCOME TAX | |||||||
| Tax Provision | -- | $17.4M | $-3.6M | $1.0M | $925.0K | ||
| NET INCOME | |||||||
| Net Income | $-10.9M | $121.2M | $-115.9M | $-136.0M | $-168.4M | ||
| Net Income (Continuing Operations) | $-10.9M | $121.2M | $-115.9M | $-136.0M | $-168.4M | ||
| Net Income (Discontinued Operations) | $-10.9M | $121.2M | $-115.9M | $-136.0M | $-168.4M | ||
| Net Income (Common Stockholders) | $-10.9M | $121.2M | $-115.9M | $-136.0M | $-168.4M | ||
| Normalized Income | -- | -- | -- | -- | $-165.8M | ||
| TOTALS | |||||||
| Total Expenses | $59.7M | $213.0M | $130.7M | $164.2M | $192.9M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $21.6M | $82.8M | $83.2M | $83.4M | $84.3M | ||
| Average Shares Outstanding (Diluted) | -- | $88.2M | $83.2M | $83.4M | $84.3M | ||
| Shares Outstanding | $82.7M | $83.2M | $83.3M | $84.2M | $85.5M | ||
| Basic EPS | $-0.51 | $1.46 | $-1.39 | $-1.63 | $-2 | ||
| Basic EPS (Continuing Operations) | $-0.51 | $1.46 | $-1.39 | $-1.63 | $-2 | ||
| Diluted EPS | $-0.51 | $1.37 | $-1.39 | $-1.63 | $-2 | ||
| Diluted EPS (Continuing Operations) | -- | $1.37 | $-1.39 | $-1.63 | $-2 | ||
| OTHER METRICS | |||||||
| Other Gand A | $21.6M | $45.8M | $48.7M | $49.9M | $48.8M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AVIR | $2.93 | +1.7% | 267.62K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Atea Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW